WHEELER CRAIG A 4

What Happened

• Craig A. Wheeler, a director of Amicus Therapeutics (FOLD), disposed of company securities on 2026-04-27 in connection with the acquisition of Amicus by BioMarin. He disposed of 84,631 reported shares (64,217 common shares + 20,414 RSUs that vested at closing) at $14.50 per share, producing $1,227,150 in cash.
• In addition, a series of stock options totaling 313,630 underlying shares were cancelled and converted into cash payments as part of the merger (each payment equal to the excess of $14.50 over the option exercise price times the number of shares). All options were fully vested and vested in full at closing.

Key Details

• Transaction date: 2026-04-27 (transaction tied to merger closing). Price for common stock: $14.50/share; cash received for common/RSU portion: $1,227,150.
• Derivative dispositions (options converted to cash): 30,000; 16,236; 19,473; 18,574; 36,111; 45,423; 30,474; 42,467; 74,872 — total = 313,630 option-equivalent shares. Reported dollar amounts for those conversions are listed as N/A in the filing because each was converted to a cash payment computed per the merger formula.
• Shares disposed included 64,217 common shares and 20,414 RSUs that vested at closing.
• Shares owned after the transaction: not specified in the provided data (check the full Form 4 for post-transaction holdings).
• Notable footnotes: (F1) common shares + vested RSUs disposed at closing; (F2) each option cancelled and converted to cash equal to (14.50 − exercise price) × shares; (F3/F4) options were fully vested and vested in full at closing.
• Filing timeliness: no late-filing flag provided in the supplied summary.

Context

• These were merger-related dispositions and option cancellations — not open-market sales. In acquisitions it is common for outstanding RSUs and options to vest and/or be cashed out per the merger agreement; the option conversions here represent cash payouts based on the transaction price less option exercise prices.
• Such merger-driven transactions reflect deal mechanics rather than routine insider sentiment; they should be interpreted differently than voluntary open-market purchases or sales.